Vol. 02 NO 9
NEWS - PAGE 2
FLIPKART FOUNDER FUNDS BANGALORE
BASED 3D PRINTED HUMAN LIVER
TISSUE STARTUP
First Human-Sheep Hybrid
STANFORD SCIENTISTS
DEVELOP FIRST
HUMAN-SHEEP HYBRID
The human-sheep chimera spells good news
for people suffering from type 1 diabetes, in
addition to holding potential for mass-pro-
duction of human organs for transplants.
Building on a controversial breakthrough
made in 2017, the scientists this week, were
able to grow a sheep embryo injected with
adult human stem cells for 28 days, including
21 days inside a sheep, it was announced at a
meeting of the American Association for the
Advancement of Science in Austin, Texas.
The human portion of the embryos created in
the experiment is exceedingly small, but the
fact it exists at all is what generates consid-
erable controversy in this field of research.
“The contribution of human cells so far is
very small. It’s nothing like a pig with a hu-
man face or human brain,” stem cell biolo-
gist Hiro Nakauchi told media at a presenta-
tion of the research this week in Austin, Texas,
explaining that, by cell count, only about one
in 10,000 cells (or less) in the sheep embryos
are human.
The experiment had to be terminated, as the
law prohibits developing cross-species em-
bryos, called chimera, for more than 28 days.
GET THIS NEWSPAPER e-copy VIA WHATSAPP every week
NEWS - PAGE 6
BIODEGRADABLE BANDAGES EXPEDITE
NORMAL REGENERATION OF BURNT
TISSUE
The embryos, which were not allowed to de-
velop past 28 days of age, move researchers a
small step closer to perhaps growing human
organs for medical transplant.
The team say they have already been able to
use genome editing techniques to produce pig
and sheep embryos that are unable to develop
a pancreas, although they are still working on
the approach. And for such embryos to grow
and replace missing organs, Dr Hiro Nakau-
chi of Stanford University, who is part of the
team, said a longer experiment, perhaps up to
70 days, would be more convincing, although
that would require additional permission
from institutional review boards.
“Even today the best matched organs, ex-
cept if they come from identical twins, don’t
last very long because with time the immune
system continuously is attacking them,” says
another lead of the team, reproductive biolo-
gist Pablo Ross from the University of Cali-
fornia, Davis.
Although it’s still a long way off, organs
produced in interspecies chimeras could be
one way of producing enough supply to meet
demand – by transplanting, say, a hybridised
SCHOLARSHIP - PAGE 7
APPLY FOR PHD UNDER STARS –
SUPPORTING TALENTED PHD RESEARCH
STUDENTS @ CHARLES UNIVERSITY, PRAGUE
By Disha Padmanabha
pancreas, from a sheep or pig, to a desper-
ate patient. For the transplant to work, the
researchers think at least 1 percent of the em-
bryo’s cells would need to be human – mean-
ing these first steps demonstrated in the sheep
are still very preliminary.
As work continues, ethical scrutiny will
also surely intensify. Ross and his colleagues
acknowledge the controversial nature of their
work, but they also say that they’re moving
cautiously. Ross, for one, sees the ever-wid-
ening approaches for organ research as cause
for optimism.
“All of these approaches are controversial,
February 27th, 2018.
NEW JOBS AVAILABLE
PAGES 11-12
Breakthrough Alert!
The quest to create animals with human
organs has a long history – and it is now
becoming a reality. In a remarkable feat,
Stanford scientists have now created the
first successful human-sheep hybrid.
The quest to create animals with human
organs has a long history – and it is now
becoming a reality. In a remarkable feat,
Stanford scientists have now created the
first successful human-sheep hybrid.
A biomedical advance that has long
been a dream and a quandary for scien-
tists hoping to address a critical shortage
of donor organs is now reality thanks to
a Stanford University study wherein sci-
entists have successfully grown embryos
inside a surrogate for three weeks which
had both sheep and human cells.
and none of them are perfect, but they offer
hope to people who are dying on a daily ba-
sis,” he said. “We need to explore all pos-
sible alternatives to provide organs to ailing
people.”
GIVE MISSED CALL TO
080-395-34707
1
February 27th, 2018.
Flipkart Founder Funds
Bangalore Based
3D Printed Human Liver
Tissue Startup
Bengaluru-based biotechnology startup
Pandorum Technologies has reportedly raised
$3.2 million in its series A funding from Bin-
ny Bansal, Indian Angel Network (IAN) and
other high net worth individuals (HNIs).
Founded in 2011 by Arun Chandru and Tu-
hin Bhowmick, the startup works on tissue
engineering and regenerative medicine.
The startup has received Rs 7.9 crore ($1.2
million) of the Rs 21 crore and the remaining
capital will come in tranches.
After successfully 3D printing human liv-
er tissues which can be used for medical re-
search, the startup is currently bio-engineer-
ing human cornea for implants. The biotech
intends to use the funding to further scale up
its operations, hire talent and deepen its re-
search and development.
Indian Scientist
Successfully Controls
Diabetes in Animal Study
India currently faces an uncertain future in
relation to the potential burden that diabetes
may impose upon the country. And with over
62 million diabetic individuals currently di-
agnosed with the disease, it is fast gaining the
status of a potential epidemic. The aetiology
of diabetes in India is multifactorial and in-
cludes genetic factors coupled with environ-
mental influences such as obesity associated
with rising living standards, steady urban mi-
gration, and lifestyle changes.
In 2000, India (31.7 million) topped the
world with the highest number of people with
diabetes mellitus followed by China (20.8
million) with the United States (17.7 million)
in second and third place respectively. These
numbers are projected to to double globally
from 171 million in 2000 to 366 million in
2030 with a maximum increase in India.
While scientists within the country and out-
side alike are toiling away in their labs, an
NCL scientist, Dr. Srinivasa Reddy has now
been able to produce exciting results in the
field of study.
Dr. Reddy and team have been successful
in synthesizing a molecule with the help of
which they were able to control diabetes in
mouse models.
“The clinical trials have been successful,”
2
The tissues, made of human cells, would
allow for inexpensive medical research with
decreased reliance on animal and human tri-
als, and could eventually be used for liver
transplants.
The company believes their 3D bio-printed
mini-livers that mimic the human liver will
serve as reliable test platforms for discovery
and development of drugs with better effica-
cy, less side effects and at lower costs.
This flagship product was developed in
2015 and can be used in medical research for
drug metabolism and disease modelling. The
designed product can perform functions of a
human liver tissue including detoxification,
metabolism, and secretion of biochemicals
such as albumin and cholesterol.
he said while talking to Sakal Times. “We
have identified a molecule which can keep
the sugar levels in the permissible limits. We
have successfully conducted a few trials on
mice. For this diabetes trial, we had collab-
orated with Shantani Proteomics. We have
to collaborate with biologists for trials on
animals. The data so far collected from the
research is interesting and we are further de-
veloping it.”
“I am working in the area of total synthesis
of biologically active natural products and
medicinal chemistry using ‘silicon incorpo-
ration approach’. Macrocyclic natural com-
pounds and silicon incorporation in known
drug scaffolds with an ultimate aim of dis-
covering drugs are the special interests.”
A well-experienced intellect, Dr. Reddy,
spearheaded the group which has now syn-
thesized over 25 natural products that retain
their native biological function. A few recent
achievements of his include the identification
of potential leads in an antibiotic compound
based on a hunanamycin natural product for
treating food infections, an anti-diabetic mol-
ecule in collaboration with an industry part-
ner and anti-TB compound using a strategy
called ‘repurposing of a drug scaffold’.
By Disha Padmanabha
SCIENTISTS DEVELOP $2 PER GENE
DIY SEQUENCING TECH
Improving our ability to construct and func-
tionally characterize DNA sequences would
broadly accelerate progress in biology. But
the speed breaker pops up in the form of ex-
penses- currently, gene sequences from com-
mercial vendors cost approximately $50 to
$100 per gene.
Studies being pursued in a wide range of
subjects in medicine- from antibiotic re-
sistance to cancer – require conducting
“high-throughput” experiments, where scien-
tists screen hundreds or thousands of groups
of cells simultaneously. Analyzing large
numbers of cells, each with slight differences
in their DNA, for their ability to carry out a
behavior or survive a drug treatment can re-
veal the importance of particular genes, or
sections of genes, in those abilities.
And given the current climate, sequencing
genes for such studies involve high cost.
Therefore, UCLA scientists have now pio-
neered a new technique that allows for cheap-
er and easier sequencing strategies.
The approach, DropSynth, enables scien-
tists in any typical biochemistry laboratory
to make their own gene sequences for only
about $2 per gene.
“Our method gives any lab that wants the
power to build its own DNA sequences,” said
Sriram Kosuri, a UCLA assistant professor
of chemistry and biochemistry and senior au-
thor of the study. “This is the first time that,
without a million dollars, an average lab can
make 10,000 genes from scratch.”
“There’s an ongoing need to develop new
gene synthesis techniques,” said Calin Ple-
sa, a UCLA postdoctoral research fellow and
co-first author of the paper. “The more DNA
you can synthesize, the more hypotheses you
can test.”
Another drawback of the current methods
for synthesizing genes, he says is that fact
Vol. 02 NO 9
By Disha Padmanabha
that they either limit the length of a gene to
about 200 base pairs- the sets of nucleotides
that made up DNA- or are prohibitively ex-
pensive for most labs.
The team’s new method involves isolating
small sections of thousands of genes in tiny
droplets of water suspended in an oil. Each
section of DNA is assigned a molecular “bar
code,” which identifies the longer gene to
which it belongs. The sections which initial-
ly are present in only very small amounts,
are then copied many times to increase their
number. Finally, small beads are used to sort
the mixture of DNA fragments into the right
combinations to make longer genes, and the
sections are combined. The result is a mix-
ture of thousands of the desired genes, which
can be used in experiments.
In order to test this out, the scientists used
DropSynth to make thousands of bacteri-
al genes- each as long as 669 base pairs in
length. Each gene encoded a different bacte-
rium’s version of the metabolic protein phos-
phopantetheine adenylyltransferase, or PPAT,
which bacteria need to survive. Given PPAT
is critical to bacteria that cause everything
from sinus infections to pneumonia and food
poisoning, it’s being studied as a potential an-
tibiotic target.
The researchers created a mixture of
the thousands of versions of PPAT with
DropSynth, and then added each gene to a
version of E. coli that lacked PPAT and tested
which ones allowed E. coli to survive. The
surviving cells could then be used to screen
potential antibiotics very quickly and at a low
cost.
The team is still working on reducing
DropSynth’s error rate. In the meantime,
though, the scientists have made the instruc-
tions publicly available on their website. All
of the chemical substances needed to repli-
cate the approach are commercially availa-
ble.
By Disha Padmanabha
Vol. 02 NO 9
Gut-on-a-Chip Wields
Promise for Future of
Personalized Medicine
The small intestine is the major site for
digestion, drug and nutrient absorption, in-
teraction with commensal microbiome, and
development of mucosal immunity, as well
as a primary site for many diseases, such as
bacterial, viral and parasitic infections and
inflammatory bowel disease.
And majorly attributable to the lack of hu-
man-relevant responses, many animal mod-
els unsuitable to study causal factors and
treatment strategies for human intestinal
infections and disorders, three-dimensional
(3D) human tissue surrogates, such as intesti-
nal organoids (also known as enteroids) have
emerged as promising alternatives.
Organoids faithfully recapitulate the cellu-
lar diversity of the intestinal epithelium and
are ideally suited for in situ visualization
and continuous monitoring of epithelial de-
velopment and differentiation. But the catch
is, these organoids form all of the cell types
present in human intestine, but they grow as
cysts surrounded by thick extracellular matrix
gels with their “apical” cell surface (which is
normally exposed to the content of the gut)
facing an enclosed lumen. This prevents the
study of dynamic processes involving the in-
testinal barrier, including nutrient and drug
transport, as well as its interactions with the
microbiome.
Therefore, researchers at the Wyss Institute
led by Founding Director, Donald Ingber,
M.D., Ph.D., had previously engineered a mi-
crofluidic “Organ-on-a-Chip” (Organ Chip)
culture device in which cells from a human
intestinal cell line originally isolated from
a tumor were cultured in one of two paral-
lel running channels, separated by a porous
matrix-coated membrane from human blood
vessel-derived endothelial cells in the adja-
cent channel.
Admittedly, the chip enabled new insights
into how flow and cyclic peristalsis affects
FIRST OF ITS KIND,
BIOMARKER-BASED TEST TO
INDICATE AUTISM IN CHILDREN
Scientists have now made some major
headway in the early diagnosis of autism. Re-
searchers at the University of Warwick have
developed new blood and urine tests that
could identify autism in children.
Autism spectrum disorders (ASD) are de-
fined as developmental disorders mainly
affecting social interactions and range of in-
terests and causing a wide spectrum of oth-
er disabilities, such as speech disturbances,
repetitive and/or compulsive behaviors, hy-
peractivity, anxiety, and difficulty to adapt to
new environments, with or without cognitive
impairment.
Furthermore, the high heterogeneity of the
clinical presentation makes diagnosis of ASD
difficult and uncertain, particularly at the
early stages of development. Therefore, the
researchers of the study set out to discover
and develop robust biomarkers for diagnosis
and progression of severity of ASD expecting
to facilitate earlier diagnosis and intervention
which could also potentially reveal new caus-
ative factors.
The team was led by Dr Naila Rabbani,
intestinal differentiation and function, but it
could not be used to study processes that re-
lied on normal intestinal cells from individu-
al donors.
“We are now able to leverage the organoid
approach to isolate intestinal stem cells from
human biopsies, but we break up the orga-
noids and culture the patient-specific cells
within our Organ Chips where they sponta-
neously form intestinal villi oriented towards
the channel lumen, and the epithelium in
close apposition to human intestinal micro-
vascular endothelium,” said Ingber, who is
also the Judah Folkman Professor of Vas-
cular Biology at Harvard Medical School
(HMS) and the Vascular Biology Program at
Boston Children’s Hospital, as well as Pro-
fessor of Bioengineering at Harvard’s John
A. Paulson School of Engineering and Ap-
plied Sciences (SEAS). “This approach pre-
sents a new stepping stone for the investiga-
tion of normal and disease-related processes
in a highly personalized manner, including
the transport of nutrients, digestion, differ-
ent intestinal disorders, and intestinal inter-
actions with commensal microbes as well as
pathogens.”
In the course of this study, researchers used
a microfluidic device composed of a clear,
flexible polymer containing parallel micro-
channels separated by a porous extracellu-
lar matrix membrane. One channel is coated
with human intestinal epithelial cells and the
other with human endothelial cells which
mimic the blood vessel wall.
This chip was then exposed the chip to a
radiation dose of 8 Gray, which is known
to cause gastrointestinal effects in humans.
The team then observed increases in several
markers of cell damage in both the endothe-
lial and epithelial cells: cell death, generation
Reader of Experimental Systems Biology at
the University of Warwick who said: “Our
discovery could lead to earlier diagnosis and
intervention.”
“We hope the tests will also reveal new
causative factors. With further testing we
may reveal specific plasma and urinary pro-
files or “fingerprints” of compounds with
damaging modifications. This may help us
improve the diagnosis of ASD and point the
way to new causes of ASD.”
Genetic causes are thought to be responsi-
ble for around a third of cases of ASD, while
the rest are believed to be caused by a com-
bination of environmental factors, mutations,
and rare genetic variants.
The team found a link between ASD and
damage to proteins in blood plasma. They
found the most reliable of the tests they de-
veloped was examining protein in blood
plasma, which found children with ASD
had higher levels of the oxidation marker
dityrosine (DT) and certain sugar-modi-
February 27th, 2018.
By Disha Padmanabha
A series of confocal microscopy sections taken through the intestinal epithelial and vascular channels of the primary Small Intestine-on-a-Chip visualizes first the
surface of epithelial villi-like structures (in red) and nuclei (in blue) of small intestinal epithelial cells in the intestinal channel, and then cell-cell contacts (in green) of
intestinal endothelial cells in the adjacent vascular channel. Credit: Wyss Institute at Harvard University
of reactive oxygen species, double-stranded
DNA breaks, degradation of lipids in the “This finding helps explain why other
cell membrane, and loss of microvilli struc- models of the human gut that don’t include
ture, as well as junction disruptions between endothelial cells generally fail to mimic the
neighbouring cells and of the mucous mem- gut’s response to radiation injury,” says Oren
brane that protects the intestinal wall. Levy, Ph.D., M.B.A., co-author of the paper
Interestingly, the endothelial cells in the and Staff Scientist at the Wyss Institute.
blood vessel channel had a stronger response
to radiation than the epithelial cells in the in- “More studies are needed to confirm the
testinal channel in terms of ROS generation, link between endothelial and epithelial cell
lipid degradation, and DNA fragmentation. responses, but we think that ROS generated
Furthermore, the endothelial cells experi- by endothelial cell damage will prove to be
enced peak apoptosis levels about 24 hours the driving force behind epithelial cell dam-
after exposure, while epithelial cells were age, and this could serve as a target for fu-
hardest hit at 48 hours, suggesting that the ture anti-radiation therapeutics.”
endothelium is more sensitive to radiation.
When the scientists repeated the experiment “In the future, such efforts could allow us to
on a chip that only contained epithelial cells, much better understand human-microbiome
they observed that the irradiated cells did not interactions, model malnutrition disorders
have the typical response to radiation: their and inflammatory diseases of the gut, and
microvilli were not blunted, their mucosal perform personalized drug testing,” said co-
barrier was not disrupted, their cell barriers first author Alessio Tovaglieri, a Graduate
remained functional, and they had lower Student at the Department of Health Science
ROS generation. This surprising result sug- and Technology at ETH Zurich in Switzer-
gests that endothelial cells play a key role in land, who performs his thesis work on Ing-
the gastrointestinal damage observed in radi- ber’s team.
ation injury.
fied compounds called advanced glycation to develop further to more severe disease and
end-products (AGEs). The scientists further assess if treatments are working.
Genetic causes are thought to be responsible
for around a third of cases of ASD, while the However, some experts have warned that we
rest are believed to be caused by a combina-
tion of environmental factors, mutations, and
shouldn’t expect to see the Warwick team’s
blood test being used in the real world any
rare genetic variants. time soon. “There have been several attempts
The study used machine learning techniques at developing biomarkers for autism, none
to study the blood of both children with and of which have been particularly success-
without ASD in order to distinguish chem- ful,” said Autistica’s Director of Science, Dr
ical differences between the two groups. James Cusack. “This attempt is weakened by
Researchers looked at blood and urine sam- a small sample size, possible overfitting of
ples from 38 children diagnosed with ASD, data and a lack of comparison groups.”
compared to a healthy control group of 31
children. All the subjects studied were aged “This study does not tell us how effective-
between five and 12. ly this measure can differentiate between
The Warwick team discovered there were autism and other neurodevelopmental or
chemical differences between the two mental health conditions such as ADHD and
groups. Working with a further collaborator anxiety…The design of the study itself is suf-
at the University of Birmingham, the chang- ficiently robust as an exploratory experimen-
es in multiple compounds were combined to- tal study, but the results cannot be used to
gether using artificial intelligence algorithm propose a potential new diagnostic measure
techniques to develop a mathematical equa- at this stage.”
tion to distinguish between ASD and healthy
controls. The outcome was a diagnostic test Surely, this study and what it has achieved is
better than any method currently available. highly interesting but then the outcomes are
The team believes their next step towards far-fetched. It is far too soon to say whether
establishing this as a reliable study is to repeat such tests could ever have a role in clinical
it further with a larger experimental group so practice given its various limitations; for the
as to confirm the diagnostic performance and foreseeable future, the way ASD is diagnosed
to assess if the test can identify ASD at very will remain unchanged.
early stages, indicate how the ASD is likely By Disha Padmanabha
3
February 27th, 2018.
Scientists Dig Out Genetic
Cause of Typhoid
Superbug
Typhoid fever remains a significant pub-
lic health threat in low- and middle-income
countries, with an estimated ~200,000 ty-
phoid-associated deaths each year. Caused by
Salmonella entericasubsp. enterica serovar
Typhi (S. Typhi), a human-restricted mono-
phyletic serovar of S. enterica. S. Typhi, it
is transmitted from human to human by the
fecal-oral route, often via contaminated wa-
ter. Vaccination, access to clean water, and
improved sanitation are effective means to
prevent typhoid.
After antibiotics were first introduced to
treat typhoid in the 1940s, typhoid’s mortali-
ty rate plummeted from around 26 percent to
just 1 percent. But within 20 years the first
cases of typhoid resistant to chlorampheni-
col—one of the three first-line treatments for
typhoid appeared signaling a battle between
antibiotic and bacteria.
Typhoid strains resistant to all three first-
line treatments, which are known as multi-
drug-resistant (MDR) typhoid strains were
quick to follow those resistant to only one
antibiotic. And when doctors began using
second-line antibiotics (more modern but
expensive versions) such as fluoroquinolo-
nes, typhoid followed with resistance against
those drugs, too.
Now, the Salmonella enterica serovar Typhi
Virtual 3D Human Cancer
Tissues to Accelerate,
Enhance Research
Three researchers from the University of
Newcastle and the Hunter Medical Research
Institute (HMRI) have now designed the
world’s first online platform that houses 2D
and 3D microscopy datasets of valuable clin-
ical human cancer biopsy samples, revolu-
tionising the way researchers access critical
information needed to advance cancer treat-
ment.
Jamie Flynn, Antony Martin and William
Palmer, in collaboration with the Hunter
Cancer Biobank, created a virtual database
that displays 3D image datasets alongside
traditional 2D micrographs used by pathol-
ogists and researchers. According to website
information, each dataset is furnished with
detailed, de-identified clinicopathological
and technical metadata in order to provide
context for further research. Physical samples
associated with each dataset can also be ob-
tained from the source biobank, using provid-
ed contact details. Importantly, the datasets
have been made available to both researchers
and the general public to encourage greater
utilisation of clinical data.
Currently, tumour samples can be obtained
from physical biobanks to conduct investiga-
tions. But the process is riddled with obsta-
cles, including lengthy ethics applications,
long wait times and high costs. Once a sam-
ple is obtained, it can only be used for a sin-
gle experiment. This is acknowledged as less
than satisfactory, especially in the case of rare
tumours, where samples are hard to source.
4
strain behind a current outbreak has acquired
a plasmid that renders it resistant to five
classes of antibiotics, according to an analy-
sis from an international team of researchers.
A typhoid fever outbreak emerged in Pa-
kistan in November 2016, with a number
of cases, especially in Sindh Province, re-
sistant to ceftriaxone, a third-generation
cephalosporin, and to the first-line drugs
chloramphenicol, ampicillin, and trimethop-
rim-sulfamethoxazole. The strains were also
resistant to fluoroquinolones, which are used
to treat multidrug resistant cases.
Now, a study by researchers at the Well-
come Sanger Institute shows the typhoid
strain causing the outbreak acquired an ad-
ditional piece of DNA to become resistant to
multiple antibiotics, including a third-gener-
ation antibiotic.
In the spring of 2017, collaborators Pro-
fessor Rumina Hasan and Dr Sadia Shakoor
from the Aga Khan University in Pakistan
contacted the Wellcome Sanger Institute to
genetically analyse the outbreak. Sanger In-
stitute scientists performed whole genome
sequencing of typhoid samples from Pakistan
to investigate the genetic cause behind its
high level of antibiotic resistance.
In the course of their study, the team was
able to discover the strain behind the out-
“It currently takes many months before re-
searchers are able to obtain tissue samples
from a physical biobank and carry out in-
vestigations with it. Once a researcher has
performed their study, that sample typically
cannot be reused. Each digital cancer sam-
ple in The Virtual Biobank is made up of high
resolution microscopy images in both 2D and
3D, plus important clinical and molecular
information that provides the foundation for
virtual research into cancer.
“We’ve taken a tiny sample from tumor bi-
opsies stored at the Hunter Cancer Biobank
and converted them into a virtual copy, en-
abling anyone around the world with an in-
ternet connection to carry out research from
their computers or easily request access to
the physical sample they need.
“This process ensures the physical sample
remains intact, but a 3D, digital copy with
clinical and experimental information is kept
online for future use. This is particularly
critical for rare cancers, which are hard to
study due to a limited number of samples,”
Dr Flynn explained.
In the course of their work, the researchers
used a hand-built laser microscope, engi-
neered to create these advanced 3D images.
Instead of analyzing a thin slice of the sam-
ple, the CLARITY light-sheet produces clear,
detailed 3D images of the whole tissue at a
cellular level in a process that only takes a
break, strain H58, a strain known to be as-
sociated with multidrug resistance. When
researchers looked further, they found this
strain of H58 had gained an extra strand of
bacterial DNA – a plasmid – that encoded for
additional antibiotic resistance genes. The ty-
phoid possibly picked up the plasmid from
E. coli.
“This is the first time we have seen an out-
break of extensively drug-resistant typhoid,”
said Elizabeth Klemm, who co-led the anal-
ysis work at the Sanger Institute. “This out-
break was caused by a multidrug-resistant
strain that had gone a step further and ac-
quired an extra piece of DNA encoding addi-
tional genes for antibiotic resistance.”
Charlie Weller, head of vaccines at Britain’s
Wellcome Trust global health charity, said
the findings were a clear warning that “treat-
ment options for typhoid are running out”
and focussing on prevention was now vital.
Professor Gordon Dougan, a senior author
from the Wellcome Sanger Institute and Uni-
versity of Cambridge Department of Medi-
cine, said: “We have used genetic sequenc-
ing to uncover how this particular strain of
typhoid became resistant to several key anti-
Jamie Flynn, Antony Martin and William Palmer, in collaboration with the Hunter Cancer Biobank, created a virtual database that displays 3D image datasets
alongside traditional 2D micrographs used
few minutes.
The Biobank, further, includes a “Tissue
Tracker” that automatically collects metadata
so that all new tissue samples can be cata-
loged and experiments easily replicated.
While still in its early stages, the online
platform holds promising future potential in
areas of research, education and even virtual
reality.
“The technology and tools that we’ve put
together make this data available to anyone
in the world. People in the fields of engineer-
ing or computer science can now easily ap-
ply their knowledge to questions surrounding
cancer. Educators can also access the site
and use real-world examples to teach pathol-
ogy to the next generation of cancer clini-
cians and researchers.
“We’d also like to convert the 3D data
Vol. 02 NO 9
biotics. Sporadic cases of typhoid with these
levels of antimicrobial resistance have been
seen before, but this is the first time we’ve
seen an ongoing outbreak – which is con-
cerning.”
Dr Elizabeth Klemm, co-first author from
the Wellcome Sanger Institute, said: “Antibi-
otic resistance has been mounting in typhoid
for decades. This outbreak was caused by a
multidrug-resistant strain that had gone a
step further and acquired an extra piece of
DNA encoding additional genes for antibiotic
resistance. We therefore classified this strain
of typhoid as extensively drug-resistant. This
is the first time we have seen an outbreak of
extensively drug-resistant typhoid.”
Dr Charlie Weller, Wellcome’s Head of Vac-
cines, said: “The treatment options for ty-
phoid are running out. It’s time we focus on
prevention, in addition to treatment. Vaccines
offer another way to tackle drug resistant in-
fections and we have a unique opportunity to
address typhoid with a new Typhoid Conju-
gate Vaccine that has been recently prequali-
fied by the World Health Organisation.”
By Disha Padmanabha
By Disha Padmanabha
into virtual reality for education and gener-
al awareness. Hopefully soon, anyone with
a smartphone and Google Cardboard could
experience the internal environment of can-
cer tissue and bring about new insights,” Dr
Palmer said.
The cell nuclei are pictured here in red and the background structures and
fibers are green in a 3D breast cancer biopsy (0.06 inches in diameter)
(Credit: University of Newcastle)
Vol. 02 NO 9
Induced Pluripotent Stem
Cells Hold Potential as
Cancer Vaccines:
Stanford Study
Nearly a century ago, researchers observed
that immunization with embryonic materials
led to the rejection of transplanted tumors.
More recently, studies identified shared tran-
scriptome profiles and antigens on various
tumor cells and embryonic cells. This has
led to the hypothesis that embryonic stem
cells (ESCs) could be used as immunization
agents to promote an anti-tumor response.
And exploring this cancer-fighting strategy,
scientists have now been able to successfully
immunise mice against breast, lung and skin
cancers, raising hopes that a human cancer
vax could be just around the corner.
Like cancer cells, iPS cells can propagate
indefinitely. They can be coaxed to assume
many different kinds of cells, making them
the perfect ingredient in regenerative medi-
cine, and best of all, they can be generated
from adult stem cells.
“We’ve learned that iPS cells are very sim-
ilar on their surface to tumor cells,” said
Joseph Wu, MD, PhD, director of Stanford’s
Cardiovascular Institute and professor of
cardiovascular medicine and of radiology.
Flu Kill Pill Wipes off
Viruses Within 24 Hours
Japanese pharmaceutical company, Shion-
ogi & Co., has now claimed that its experi-
mental drug can rid flu suffers of their symp-
toms in as little as a day, but the sad part is the
drug will be no good to this year’s epidemic
because it won’t be available to the United
States until 2019.
Baloxavir, the flu drug discovered by Osa-
ka, Japan-based Shionogi, received prelimi-
nary approval in Japan last week. Japanese
and American flu patients who took part in
the recent clinical trial of the Shionogi & Co.
pill are said to have had the virus wiped out
from their bodies in about 24 hours through
a single dose.
The experimental drug worked three times
faster than another antiviral drug, Tamiflu,
the company told the The Wall Street Journal.
Tamiflu, which generated more than $3 bil-
lion in sales when swine flu sparked a global
contagion in 2009, reduces the duration of
illness by only up to a day if it’s taken within
the first 48 hours of the onset of symptoms.
What’s more, some seasonal strains have de-
veloped mutations that decrease its potency,
spurring calls for alternatives.
While the overall time to alleviation of
symptoms was similar whether participants
took baloxavir marboxil or oseltamivir(sold
under the brand name Tamiflu), Shionogi
says its experimental drug provides immedi-
ate relief faster, which might curb the virus’s
contagiousness in people who take the treat-
ment.
“The advantage is that it’s one pill once,
versus a course of therapy, so particularly
“When we immunized an animal with genet-
ically matching iPS cells, the immune system
could be primed to reject the development of
tumors in the future. Pending replication in
humans, our findings indicate these cells may
one day serve as a true patient-specific can-
cer vaccine.”
“These cells, as a component of our pro-
posed vaccine, have strong immunogenic
properties that provoke a systemwide, can-
cer-specific immune response,” said Koore-
man, who is now a surgery resident in the
Netherlands. “We believe this approach has
exciting clinical potential.”
In the course of their study, the team admin-
istered a group of mice the potential cancer
vaccine – genetically matched, inactivated
iPSCs in combination with a generic im-
mune-stimulating agent known as an adju-
vant. After four weekly injections of the vac-
cine, the mice were implanted with mouse
breast cancer cells.
In the control groups the cancer grew and
developed, but in 70 percent of the vaccinat-
for pandemic planning, this could be an ad-
vantage,” the head of co-developer Roche’s
pharma unit, Daniel O’Day, told Bloomberg.
“You don’t have the potential resistance
that comes with not completing your course
of therapy.”
According to Japanese newspaper The Asa-
hi Shimbun, the drug, which targets both the
A and B types of influenza virus, received
a green light from a Japanese government
health ministry panel in early February, indi-
cating a likely go-ahead for imminent manu-
facture and sale of the drug.
By Disha Padmanabha
ed mice the tumors reduced in size signifi-
cantly, while cancer cells were completely
eliminated in two mice, which went on to live
for over one year following the experiment.
The results were subsequently replicated us-
ing skin cancer and lung cancer cell lines.
In a second experiment, researchers inocu-
lated mice with the iPSC vaccine and then in-
jected them with mesothelioma cells, a form
of lung cancer. Compared to mice that had
not been vaccinated, those that got a mix-
ture of stem cells and the immune booster
mounted a robust defense against the can-
cer. In mice whose immune responses were
strongest and most narrowly focused on the
tumors, lung cancers were least likely to take
hold and grow.
A third experiment using skin cancer cells
demonstrated that an iPSC vaccine might
be useful in preventing cancer recurrence or
metastasis after an existing tumor has been
surgically removed.
First Concussion-Detecting Blood Test
Approved by the FDA
The U.S. Food and Drug Administration has
now approved a blood test that can quickly
and reliably detect signs of a concussion.
The Brain Trauma Indicator, marketed by
Banyan Biomarkers Inc., measures the levels
of two proteins — called UCH-L1 and GFAP
— whose elevated presence suggests a cer-
tain type of brain damage normally only visi-
ble on a CT scan. Test results currently can be
available within three to four hours.
Concussion-related brain damage has be-
come a particularly worrisome public health
issue in many sports, especially football, af-
fecting the ranks of professional athletes on
down to the young children in Pop Warner
leagues. Those concerns have escalated so far
that it has led to a decline in children partici-
pating in tackle sports.
Patients with a positive test would need a
CT scan to confirm the results and determine
if surgery or other treatment is needed. The
test will first be used in emergency rooms,
possibly as soon as later this year, but Ban-
yan’s hope is that it will eventually be used
on battlefields and football fields.
FDA Commissioner Dr. Scott Gottlieb said
the test fits with the agency’s goals for deliv-
ering new technologies to patients and reduc-
ing unnecessary radiation exposure.
In a large prospective study of 1947 individ-
ual blood samples from adults suspected of
having mTBI/concussion, the Brain Trauma
Indicator was able to predict the presence of
intracranial lesions on CT 97.5% of the time
and the absence of intracranial lesions on CT
99.6% of the time.
“Helping to deliver innovative testing tech-
February 27th, 2018.
“This approach is particularly powerful
because it allows us to expose the immune
system to many different cancer-specific
epitopes simultaneously,” Kooreman said.
“Once activated, the immune system is
on alert to target cancers as they develop
throughout the body.”
The researchers next would like to study
whether the approach works in samples of
human cancers and immune cells in a labora-
tory setting. If successful, they envision a fu-
ture in which people could receive a vaccine
comprised of their own irradiated iPS cells as
a way to prevent the development of cancers
months or years later.
“Although much research remains to be
done, the concept itself is pretty simple,” Wu
said. “We would take your blood, make iPS
cells and then inject the cells to prevent fu-
ture cancers. I’m very excited about the fu-
ture possibilities.”
By Disha Padmanabha
nologies that minimize health impacts to pa-
tients while still providing accurate and reli-
able results to inform appropriate evaluation
and treatment is an FDA priority. Today’s ac-
tion supports the FDA’s Initiative to Reduce
Unnecessary Radiation Exposure from Med-
ical Imaging—an effort to ensure that each
patient is getting the right imaging exam, at
the right time, with the right radiation dose,”
said FDA Commissioner Scott Gottlieb, M.D.
“A blood-testing option for the evaluation of
mTBI/concussion not only provides health-
care professionals with a new tool, but also
sets the stage for a more modernized stand-
ard of care for testing of suspected cases.
In addition, availability of a blood test for
mTBI/concussion will likely reduce the CT
scans performed on patients with concussion
each year, potentially saving our health care
system the cost of often unnecessary neuro-
imaging tests.”
By Disha Padmanabha
5
February 27th, 2018.
Biodegradable Bandages
Expedite Normal
Regeneration of Burnt
Tissue
Russian scientists have now constructed bi-
odegradable bandages using nanofibers made
of polycaprolactone modified with a thin-
film antibacterial composition and plasma
components of human blood. The NUST MI-
SIS University claim the bandages accelerate
the growth of tissue cells twice as quickly,
contributing to the normal regeneration of
damaged tissues, as well as preventing the
formation of scars in cases of severe burns.
Scar tissue mainly consists of irreversible
collagen and significantly differs from the
tissue it replaces, having reduced functional
properties. Therefore, as a solution to this
Campus Fellows Program
@ NCBS | Consolidated
Salary of Rs. 90,000 p.m.
Purpose:
The Campus Fellows Program is targeted at
postdoctoral scientists of exceptional talent,
and provides them broad independence and
support to carry out their research in a host
laboratory at NCBS or inStem. Fellows are
expected to drive new research directions in
their host laboratories, and to establish them-
selves as independent scientists.
What’s Included?
Campus Fellows are appointed for a period
not to exceed 4 years, contingent on success-
ful annual review every year. The Fellowship
provides a consolidated salary of Rs. 90,000
per month as well as campus housing. The
program is flexible: Fellows may choose to
hold a part of their Fellowship off-campus
for collaborative work and training relevant
to their program of research. During their
tenure, Fellows are also eligible to apply for
external competitive awards.
Eligibility:
Candidates should not have more than 4
years of postdoctoral research experience.
Fellows must be sponsored by a local host
who is a member of NCBS/inStem Faculty.
6
was sought by designing biodegradable fib-
ers and multifunctional bioactive nanofilms,
which in turn help the bandages prevent scar-
ring and accelerate tissue regeneration.
A significant acceleration of the healing
process, the successful regeneration of nor-
mal skin covering tissue, and the prevention
of scarring on the site of burnt or damaged
skin have been observed when applying these
bandages made of the developed material to
an injured area.
The antibacterial components of multifunc-
tional nanofibers decrease inflammation, and
the blood plasma with an increased platelet
SCHOLARSHIPS
Application Process:
Your full application package as a single
collated PDF should consist of the following:
Your latest CV
A research proposal with detailed plans and
timelines of the project, developed in close
collaboration with your proposed host. The
length should not be more than 4-5 pages in-
cluding references.
PDF versions of 1 to 3 first-author publi-
cations.
In addition, we require the following: –
• A letter of support from your proposed
host (emailed directly to acadoffice@
ncbs.res.in)
• At least 2 letters of references (emailed
directly by the referees to acadoffice@
ncbs.res.in)
Deadlines:
There are two calls each year. This is the
first call in 2018, full applications must be re-
ceived by the Academic Office (acadoffice@
ncbs.res.in) by 31st March 2018. Short-listed
candidates will have to present their research
proposal and will be interviewed by the pan-
el in the last week of April 2018. Decisions
will be announced within 2 weeks of the in-
terviews.
The next call will be in August, 2018.
Contact Us:
Please write to acadoffice@ncbs.res.in
for any queries related to this program.
level – vital and multi-purposed for every el-
ement in the healing process – stimulates the
regeneration of tissues.
Attributable to the difficulty and pain as-
sociated, the bandages, are advised not to be
removed or changed during treatment- after
a certain period of time, the biodegradable
fiber will simply dissolve without any side
effects.
“With the help of chemical bonds, we were
able to create a stable layer containing blood
plasma components (growth factors, fibrin-
ogens, and other important proteins that
promote cell growth) on a polycaprolactone
base. The base fibers were synthesized by
electroforming. Then, with the help of plasma
treatment, to increase the material`s hydro-
Research Scholars
Program @ NIAB – NIAB’s
RSP 2018-2019
Candidates with a Master’s degree in any
branch of Life Science (M.Sc., M.Tech.,
M.V.Sc., or M.Pharm) are eligible to apply
online for a Research Scholars Program
that is available at NIAB – National Insti-
tute of Animal Biotechnology as Per the
details posted below.
Advertisement No. RSP-1/2018
Admission for Research Scholars Program
National Institute of Animal Biotechnology
(NIAB) invites applications for its Research
Scholars Program 2018-2019.
NIAB is an autonomous and premier in-
stitute of the Department of Biotechnology
(DBT),Government of India. The Institute
wishes to develop and harness novel and
emergingbiotechnological tools and applica-
tions, and take up research in cutting-edge ar-
eas forimproving animal health and produc-
tivity as well as contribute to human health
and welfare.
NIAB’s current research interests include
• host-pathogen interactions and pathog-
enomics
• next generation vaccines, diagnostics,
adjuvants and drug delivery platforms
• nutrition, metabolomics and metabolic
Vol. 02 NO 9
philic properties, a polymer layer containing
carboxyl groups was applied to the surface.
The resulting layer was enriched with anti-
bacterial and protein components”, noted
Elizabeth Permyakova, one of the project
members and laboratory scientists.
The research team has already conducted
a series of pre-clinical trials jointly with the
Research Institute of Experimental and Clini-
cal Medicine (Novosibirsk, Russia).
In vitro results have shown that with the
application of these innovative bandages the
regeneration process has been accelerated
twice as quickly. In the near future, the team
expects to get results of in vivo drug testing.
By Disha Padmanabha
disorders
• genetics and genomics
• gene and protein engineering
• reproductive biotechnology
• transgenic technology
• bioinformatics
• human-animal interface and One
Health
Applications are invited for NIAB’s RSP
2018-2019 from highly motivated individ-
uals who have secured national fellowships
and who are willing to take up research work
to meet the challenges in the above-men-
tioned areas. Those admitted as Research
Scholars could be registered for PhD through
a recognized University or through Region-
al Centre of Biotechnology, Faridabad, after
completion of course work and any addition-
al requirements.
Eligibility and Selection Criteria:
Individuals desirous of seeking admission
must have a Master’s degree in any branch
of Life Science (M.Sc., M.Tech., M.V.Sc.,
or M.Pharm). Candidates must also have
secured CSIR/UGC/DBT/ICMR/INSPIRE
NET JRF/UGC-RGNF or any other national
research fellowship for 5 years. Applications
will also be accepted from candidates who
have secured a fellowship and have com-
pleted or are likely to complete the required
courses in the academic year 2018-19.
Fellowship :
Having a fellowship is mandatory for con-
sideration. The terms and conditions, fel-
lowship amount etc. will be governed by the
awarding funding agency subject to the Rules
and conventions of the Institute.
Application and Selection Procedure:
Candidates who meet the above eligibility
criteria may apply online (link at www.niab.
org.in). The online application facility will
Next Page>>>>
Vol. 02 NO 9
be open from 19/02/2018 to 05/03/2018. No
need to send the print out of applications.
Applicants having difficulty in accessing the
portal may contact “The Senior Manager,
National Institute of Animal Biotechnology
(NIAB) at 040-2304-9403 or admin@niab.
org.in. Applications found to be in order will
be screened, and only short-listed candidates
will be called for interview to be conducted
on 26/03/2018.
Candidates must make their own arrange-
ments for any travel, boarding and lodging.
No TA/DA will be paid by NIAB for attend-
ing the interview.
The results will be announced within a
week of the interview. Selected candidates
are expected to join the RSP by 15/04/2018.
Those who have secured a fellowship and
have completed or are likely to complete
the required courses in the current academic
year, will be admitted provisionally pending
satisfactory fulfilment of the requirements at
the time of joining. Reservations are as per
statutory norms. Single room hostel facilities
will be provided.
NIAB reserves the right to accept / reject
applications or candidature or admission
in case of any discrepancy observed at any
stage.
Important Dates:
Online application facility will be open
from 19/02/2018 to 05/03/2018.
Apply For PhD Under
STARS – Supporting
Talented PhD Research
Students @
Charles University, Prague
If you hold a Master’s degree or equiva-
lent in sciences, then you are eligible to ap-
ply for the STARS – Supporting TAlented
PhD Research Students which is available
at the Faculty of Science, Charles Univer-
sity in Prague, as Per the details posted
below.
STARS – Supporting TAlented PhD Re-
search Students Call for applications – PhD
projects
What is STARS?
STARS is a program supporting talent-
ed PhD students at the Faculty of Science,
Charles University in Prague. The aim of this
program is to provide excellent education and
an adequate income to PhD students of the
Faculty. The STARS program wants to attract
the best students from the Czech Republic
as well as from abroad. Faculty of Science,
Charles University in Prague, is a top-quali-
ty centre of research in natural sciences. The
Faculty takes care about its future and that’s
why the STARS program was born. Come to
Prague and become the future of our Faculty!
Am I eligible?
The STARS program is open to all appli-
cants who hold a master‘s degree or equiv-
alent in sciences, medicine, pharmacology
and a related field of study. It is also open
to students who are in the last year of their
studies and will be able to present their de-
gree diploma at the beginning of their PhD
study. The candidate should be proficient in
English; however, no formal English exam
(such as TOEFL) is required.
How can I apply?
You can choose up to three projects (see
Open calls) for which you can then apply
through an online application form.
Find more about PhD project topics:
(https://www.biotecnika.org/2018/02/
s t a r s - s u p p o r t i n g - t a l e n t e d - p h d - re -
search-students-charles-university/)
• Comparison of immunomodulatory
properties of Mesenchymal stem cells
and Sertoli cells
• Opioid and metabolic modulation of
microglial function
• Deciphering molecular mechanisms
that govern cell expansion in Arabi-
dopsis root
• Cytosolic Iron-Suphur protein assem-
bly pathway in the amitochondriate cell
• Mitochondrion of retortamonads
• Mechanisms of host immunomodula-
tion by Trichobilharzia regenti: focus
on parasite glycans and other immuno-
logically relevant molecules
• Effect of peripheral immune response
on neuroinflammation and learning
• in cognitively advanced birds
• The role of the Jak/STAT signalling
cascade in the astrocyte clockwork of
the rat suprachiasmatic nucleus
• Dynamic structural and histochemical
February 27th, 2018.
changes in barley leaf protective mech-
anisms under elevated CO2 concentra-
tion and higher temperature
• Sexual selection and sexual trait evolu-
tion in Larix and Arabidopsis spp
• Microbial methane oxidation beneath
the Greenland ice sheet
• The role of matrix metalloproteinases
and vimentin cooperation in cancer cell
invadopodia function
• Link between chronic inflammation
and bone homeostasis failure. The role
of extracellular nucleic acids and epi-
genetic mechanisms
• The social perception of sexual dimor-
phism in human face
• Dynamics and persistence of avian
blood parasite infection
• Evolution of brain complexity and pro-
cessing capacity in reptiles and birds: A
quantitative approach to understanding
the tetrapod brain evolution
How are candidates selected?
The program is competitive. The super-
visors of the individual PhD projects will
shortlist eligible applicants, who will then be
invited for an interview to be held during the
month of March. The exact interview dates
will be agreed between the supervisors and
the candidates. Based on the interviews, the
applicants to whom the scholarship will be
offered will be selected in the beginning of
April. The program starts on October 1st.
Please do not hesitate to ask our coordina-
tors if you have any questions!
Timetable:
• January 15, 2018 - PhD research topics
and application form will be available.
• March 16, 2018 - Deadline for appli-
cation
• October 1, 2018 - Start of the program
7
February 27th, 2018.
Integrated MS-PhD
Biology Program
Admissions – August 2018
@ IISER Mohali
If you are from a Bachelor’s Degree
background and are looking for integrated
MS-PhD options, then IISER Mohali has
requested interested and eligible candi-
dates to apply online for their Biology pro-
gramme that has been advertised accord-
ing to the details posted below.
Applications are invited from prospective
candidates for admission to the Integrated
MS-PhD Program at IISER Mohali in the ar-
eas of Biology, Chemistry, Mathematics and
Physics for the session beginning in August
2018.
The programme involves course work as
well as research work. Successful completion
of the program will lead to an MS degree and
a PhD degree.
Eligibility Criteria :
The applicant should have a Bachelors de-
gree in Science and related areas with a good
academic record (at least 60% aggregate or at
least CGPI 6.0 on a scale of 10).
Additional Qualifications:
Applicants who have obtained one of the
following national-level qualifying examina-
tions, are advised to mention the same in their
application form:
1. Rank in JEST examination for Physics
2. NBHM Masters or PhD scholarship for
Mathematics
3. DST INSPIRE fellowship or KVPY
scholarship
4. Rank in IIT JAM for the chosen special-
ization
Application Procedure :
Prospective candidates should apply online
using the “Online Application Facility” by
visiting the website at http://www.iisermo-
hali.ac.in Short-listed candidates will be in-
vited for a screening-test/ interview at IISER
Mohali.
Last date : The online application facility
will be open till 12.00 noon, April 11, 2018.
For further details about the program
and research areas, please visit our web-
site: http://www.iisermohali.ac.in
8
PhD ADMISSIONS
PhD Programme
Admissions – August 2018
@ IISER Tirupati
If you are looking for admission notifica-
tions, and you are looking for appropriate
Biology and Chemistry programs, then
IISER Tirupati, has advertised for PhD
Program admissions, as Per the details
posted below.
IISER Tirupati invites applications from
prospective candidates for admission to the
Ph.D. programme, August 2018. IISER Tiru-
pati admits students in the disciplines of Bi-
ology, Chemistry, Earth & Climate Science,
Mathematics, and Physics and associated in-
terdisciplinary areas of research. In addition
to research, the programme involves course-
work and teaching assistantship.
Students with a master’s degree in Science /
Mathematics are encouraged to apply to PhD
programme.
Please note that the precise eligibility cri-
teria for August 2018 admissions may vary
from department to department and are given
below. Information about individual faculty
profiles and areas of research can be obtained
from the IISER Tirupati website.
The broad areas of research in each de-
partment include the following:
Biology:
Biophysics, Neuroscience, Plant biology,
Ecology and evolution, Cancer biology &
Immunology, Chemical Biology, Nano-Bi-
otechnology, Proteomics and Infectious dis-
ease.
Chemistry:
Bio-Organic Chemistry, Nano-technology,
Organic & Bio Molecular Chemistry, Inor-
ganic & Materials Chemistry, Theoretical,
Analytical & Physical Chemistry
Eligibility Criteria For Various Depart-
ments
(PLEASE CHECK THE TABLE ON
TOP OF THE PAGE)
General Information to the Applicants:
The candidate MUST have:
a. Qualified at least ONE of the above men-
tioned additional eligibility criteria
(OR)
b. A valid CSIR/UGC-JRF or CSIR/UGC
NET-LS (Date of examination should be
December 2015 or later) or INSPIRE-Ph.D.
fellowship
(OR)
c. IISER BS-MS (All IISERs) Dual degree
students having CGPA >= 7.0.
• The fellowships/scores/ranks must be
valid at least till August 2018. Please
note that the admission criteria can
change during the next round of admis-
sion.
• SC/ST, PD and KM candidates Per-
centage may be relaxed with 5% or 0.5
in case of CGPA.
• Candidates in the final year of their
qualifying degree are also eligible to
apply. However, their final selection
is subject to their successful comple-
tion of the qualifying degree with the
above-mentioned requirements at the
time of admission. A provisional de-
gree certificate is mandatory at the time
of admission (Scheduled to be 1st Au-
gust 2018).
Application Procedure:
Only online applications will be accepted.
Applicants can submit their forms for the re-
spective departments in the following links:
Biology(https://form.jotform.
me/80450758069463)
Chemistry(https://form.jotform.
me/80450667869470)
The candidates must carefully fill and sub-
mit the online application form on or before
April 30, 2018. Applications will be screened,
and shortlisted candidates will be intimated
further through emails only. Candidates be-
longing to reserved category will have to sub-
mit relevant certificates, if selected.
Selection Procedure:
The shortlisted candidates will be called for
interview and final selection is based on in-
terview performance.
The respective departments may use ad-
ditional criteria (based on academic perfor-
mance and/or performance in the national
Vol. 02 NO 9
level tests) to shortlist candidates for inter-
views.
Fellowship:
Upon selection and subsequently joining
the Ph.D program, candidates who do not
possess any CSIR, DBT and INSPIRE, will
be eligible for institute fellowship at par with
CSIR, DBT etc., but without HRA compo-
nent.
Please Note: All communication with can-
didates will be by email only.
Kindly check this website for periodic up-
dates.In case of any application-related spe-
cific queries, please contact the respective
departments with your application number
mentioned in the subject at the following
email addresses:
• biophdselection@iisertirupati.ac.in,
• chemphdselection@iisertirupati.ac.in
• physphdselection@iisertirupati.ac.in
• mathphdselection@iisertirupati.ac.in
• earthphdselection@iisertirupati.ac.in
Applicants age should not exceed more than
28 years at the time of joining. However, the
relaxation in age will be considered as per the
Govt. of India regulations.
Important Dates:
• Opening date of Online Application :
February 17, 2018
• Closing date of Online Application :
April 30, 2018
• Interview Dates (Tentative) : June 7,
2018 to June 14, 2018
• Application Deadline – on or before
April 30, 2018.
Vol. 02 NO 9
Integrated PhD (i-PhD)
Programme Admissions
in Biological Sciences @
IISER Tirupati
If you are looking for admission notifica-
tions, and you are looking for appropriate
Biology and Chemistry programs, then
IISER Tirupati, has advertised for Inte-
grated PhD Program admissions, as Per
the details posted below.
The integrated Ph.D. (i-Ph.D.) programme
at IISER Tirupati is aimed for highly motivat-
ed students who wish to pursue a career in re-
search. Students with an excellent academic
record can apply for the i-Ph.D. programme
upon completion of a bachelor’s degree in
any branch of science. The course combines
curricula for master’s and doctorate degrees
into a single integrated programme with a
blend of course work and research projects.
IISER Tirupati offers modern research lab-
oratories and computational facilities as well
as hostel facilities for students. Students will
also have the opportunity to participate in a
broad range of seminars, meetings and work-
shops, giving them a chance to interact with
people from other research organizations
within the country and abroad.
Overview of the i-Ph.D. programme:
IISER Tirupati offers Integrated Ph.D.
(i-Ph.D.) as a research programme with a
blend of course work (2 years) and research
projects. On successful completion of the
doctoral research project, students are award-
ed a degree in Master of Science and a Ph.D.
degree. The first four semesters consist of
core courses, elective courses and advanced
courses specializing in one subject, and com-
bined with research work. On successful
completion of course work, related project
work and a comprehensive exam, the student
continues with the research leading to a Ph.D.
The i-Ph.D. program is to be offered from
August 2018 in the Biological, Chemical,
Mathematical and Physical Sciences.
Eligibility Criteria:
1. Students with minimum 60% marks in
aggregate (overall percentage with all sub-
jects) or CGPA 6 out of 10-point scale in
B.Sc./B.Tech/B.E. or any equivalent degree.
2. In addition to the above, students must
have qualified any of the national level ex-
ams listed in the following table for the re-
spective departments.
General Information to the Applicants:
• The candidate MUST have qualified at
least ONE of the above mentioned Ad-
ditional eligibility criteria.
• The scores/ranks must be valid at least
till August, 2018. Please note that the
admission criteria can change during
the next round of admission.
• SC/ST, PD and KM candidates Per-
centage may be relaxed with 5% or 0.5
in case of CGPA.
• Candidates in the final year of their
qualifying degree are also eligible to
apply. However, their final selection
is subject to their successful comple-
tion of the qualifying degree with the
above-mentioned requirements at the
time of admission. A provisional de-
gree certificate is mandatory at the time
of admission (Scheduled to be 1st Au-
gust 2018).
Application Procedure:
Only online applications will be accepted.
Applicants can submit their forms for the
respective departments using the following
links:
Biology(https://form.jotform.
me/80450337769463)
Chemistry(https://form.jotform.
me/80452263269458)
The candidates must carefully fill and sub-
mit the online application form on or before
April 15, 2018. Only short-listed candidates
will be intimated further about the date of
interview. Candidates belonging to reserved
category will have to submit relevant certifi-
cates, if selected.
Selection Procedure:
The shortlisted candidates will be called for
interview and final selection is based on in-
terview performance. The respective depart-
ments may use additional criteria (based on
academic performance and/or performance in
the national level tests) in order to shortlist
candidates for interviews. Fellowship: Finan-
cial assistance will be provided by the insti-
tute to the selected candidates. Please Note:
All communication with candidates will be
through emails only. Kindly check this web-
site for periodic updates.
In case of any application-related queries
which are not mentioned in the FAQs, please
contact the respective departments with your
application number mentioned in the subject
at the following email addresses:
• bioiphdselection@iisertirupati.ac.in
• chemiphdselection@iisertirupati.ac.in
Important Dates:
• Opening date of Online Application :
February 17, 2018
• Closing date of Online Application :
April 15, 2018
• Interview Dates (Tentative) : June 1,
2018 to June 6, 2018
• Application Deadline – on or before
April 15, 2018
PhD Admissions in Biotech
/ Biochem /
Life Science – 2018
@ NIT Patna
National Institute of Technology Patna
invites application for admission to Ph. D
Programme in Biotech / Biochem / Com-
putational Biology, Life Science for Se-
lection through Institute Admission Test
and Interview during Even emester (Jan-
Jun’2018) for the Session 2017-18 in the
following departments as detailed below.
Chemistry Department : Chemistry, Ap-
plied Chemistry, Material Science & Tech-
nology, Bio-Chemistry, Environmental Sci-
ence, Analytical Chemistry, Bio-Technology,
Nano Science & Technology, Chemical Sci-
ence & Technology, Chemical Engineering,
Polymer Science & Technology. Pharmaceu-
tical Science, Computational Biology, Life
Science. Molecular & Biotechnology.
Categories:
Candidates with following qualifications
shall be eligible for admission to the Full-
Time Ph.D. Programme of the Institute.
Part-time Programme is only applicable for
the internal Candidates who are working as
a regular/contractual employee at NIT Patna.
The applicants seeking admission to the
Ph.D. Programme shall be classified under
any one of the following categories.
(i) Full Time Ph.D Programme:
a) With Scholarship – Funded by NIT Patna
b) With direct financial support from Govt.
/ Semi Govt. agencies such as CSIR, UGC,
DST, DAE, etc.
c) Full time Sponsored employee of PSU,
Government department, Research/Devel-
opment organization, Private Industry of re-
pute, Educational institutions Faculty/officer
as per our Ph.D regulation and sponsored
defence personnel with a minimum relevant
experience of 2 years may be considered for
admission as a sponsored full-time research
scholar.
d) Sponsored applicant will be eligible for
admission, if they are treated by their em-
ployers as on-deputation with their salary
and allowances and are relieved from their
organization/ institute for a minimum period
of two years.
e) The sponsored candidates are exempt-
ed from GATE/ NET qualification, but they
should possess the minimum entry qualifi-
cation fixed by the institute as per eligibility
criteria for full time candidate selection.
(ii) Part Time: without Scholarship – In-
ternal Candidate admitted shall be consid-
ered against supernumerary seats. and shall
not be counted against open seats notified for
admission to the program. Candidates recom-
mended by competent authority under •
Part-time category are exempted from ap-
February 27th, 2018.
pearing at Screening written rest and Selec-
tion Interview for admission. The Part-Time
Ph. D. programme candidate(s) have to con-
tinue to discharge their assigned duties along
with their research work as per the schedule
of the Ph. D. programme at the institute.
While doing Ph.D course work HoDs will re-
schedule their assign duty.
(A) NIT Patna Employees (Faculty and
Staff) may be admitted to Ph. D. programme
as a Part- time Internal candidate, provided.
a) The employees of the Institute have com-
pleted two years of regular service and are
also confirmed in his/her service at this in-
stitute.
b) Employees who have been recruited
against open advertisement on pay scale of
the institute are only eligible. The employ-
ees appointed and paid by the project fund or
from any other temporary grant will not be
treated as internal candidate under the cate-
gory of employee of the institute.
c) The minimum eligibility of Degree and
GATE/ NET requirement is mandatory for
teaching /non-teaching employee(s) of NIT
Patna having served less than 2 years at NIT
Patna.
Those who have completed two years of
regular service and are confirmed in the ser-
vices are exempted from GATE/ NET pro-
vided they fulfill the minimum eligibility
criteria.
(B) NIT Patna Faculty Appointed on
Consolidated salary: and presently working
in the Institute may be considered for admis-
sion to the Doctoral program. Provided the
candidate
a) Fulfills minimum eligibility of qualifica-
tion and GATE/ NET requirement for admis-
sion. and will be governed by the regulation
of the Doctoral program.
b) Having completed at least ONE year of
service in the institute and likely to contin-
ue on the post in the Institute for at least one
year in continuation, may be considered on
the recommendation of the HoD(s) of the de-
panment.
c) In case of continuing on the post and
drawing salary (as applicable). will not be el-
igible for Institute Scholarship.
d) After termination of the contract, No
Institute Scholarship will be admissible and
candidate will continue as self-Sponsored
candidate. and continue to be governed by
the regulation of the Doctoral program.
(C) JRF/ SRF under externally funded
Projects: – appointed and presently working
in the Institute may be considered for admis-
sion to the Doctoral program, provided the
candidate
a) Fulfills minimum eligibility of qualifica-
tion requirement for admission, and will be
governed by the regulation of the Doctoral
program.
b) Having completed at least ONE YEAR
as JRF/ SRF in the Institute and likely to con-
tinue due to his/ her satisfactory performance
and research work.
c) The Principal lnvestigator(s) (Pl) of
the Project may recommend for admission
(based on his work performance and research
work), after approval of it by the DRC.
d) The JRF/ SRF is likely to continue un-
der the project. He/ she will continue to draw
salary as applicable and are not eligible for
Next Page>>>>
9
February 27th, 2018.
Institute Scholarship.
e) After termination of contract, Institute
Scholarship will not be admissible and can-
didate will continue as self-Sponsored candi-
date, and shall continue to be governed b) the
regulation of the Doctoral program.
Eligibility Criteria For Selection For the
Full-Time Candidate:
Candidates with following qualification
will be eligible for admission to the Ph. D.
Programme of the Institute.
M. Sc./ M. Com./ MBA/ MA or equivalent
degree in relevant and related discipline with
at least 6.0 CGPA (in the scale of 10) or 55
percent marks or equivalent in aggregate
from a recognized institute or university.
Candidates with M. Sc./ M. Com./ MBA/
MA or equivalent degree from IITs/ NITs/
CFTI/ SFTI or Central/ State University in
relevant discipline are required to produce a
proof of having qualified GATE/ JAM/ JEST/
CAT/ NET/ SLET/ JRF or equivalent nation-
al eligibility test while taking admission in
the master degree in the relevant discipline
OR has valid Score in one of the national el-
igibility test.
B. Tech/ 8.E./ 8. Arch or equivalent degree
in relevant discipline with at least 8.5 CGPA
(in the scale of 10) or 80 percent marks in ag-
gregate fom a recognized technical institute
or university. with a valid GATE/ NET/ JAM/
JEST qualifying score is mandatory.
a. Must have passed the qualifying exami-
nation in Single attempt without any backlog
or failure in any semester from IITs/ NITs/
CFTI/ SFTI or Central/ State University
b. Has not graduated earlier than one year,
and holds rank of I to 10 in his/her graduating
branch from where graduated.
The minimum COPA/ marks percentage
shall be relaxed by 0.5 CGPA or 5 percent in
case of candidates belonging to the SC/ ST/
PwD categories in all cases.
Admission Procedure and Other Details:
Admission to the Ph. D. Programme shall
be made by the Institute based on minimum
eligibility criteria for the programme and
selected after evaluation of the candidate in
Screening written Test and/or selection Inter-
view conducted by the respective DRC.
Candidates’ name with application num-
ber, fulfilling minimum eligibility criteria for
admission to the respective department and
programme will be displayed on the Institute
website as per admission schedule.
DRC of the respective department will con-
duct screening written Test and Selection In-
terview. The final selection will be done after
Selection Interview.
Following type candidates with minimum
eligibility qualification are exempted from
10
appearing screening written test for admis-
sion in Ph. D Program:
i) Having qualified National Level Ex-
amination/ Scholarship such as GATE/ IN-
SPIRE/ UGC­NET/ CSIR-NET or any other
at National Level Fellowship/ Scholarship.
ii) Teaching/ non-teaching employees.
Contractual teaching faculty and JRF/SRF
of externally funded research project of the
Institute.
iii) Candidates with Master’s Degree from
IIT(s), NIT(s) and IIIT(s) with minimum 8.5
CGPA and fulfilling all other requirements as
stated in the admission notice.
A merit list is prepared after written test and
interview and admission is strictly based on
merit subject to verification of documents &
original certificates.
Scholarship & Financial Assistance for
Ph. D. Programme:
Institute Research Fellowship will be avail-
able to the eligible students as per MHRD,
GOI norms. The period and amount of re-
search fellowship shall be as per notification
of the competent authority from time to time.
Note: The scholarships from any other
agency/ organization are governed by rules
and regulation of funding agency only, and
students shall be governed by their rules only.
Documents required to be submitted
along with the downloaded application
form:
The candidates are required to submit fol-
lowing documents along with the application
form:
a. Photocopy of High School Certificate
b. Photocopies of all Mark sheets
c. Certificate of sponsorship in the pre-
scribed format (if applicable).
d. A photocopy of GATE/NET or equivalent
score card
e. A photocopy of the certificate of Caste (if
applicable).
Documents required for verification dur-
ing the interview and admission:
(i) The candidates are required to bring fol-
lowing documents at the time of written Ex-
amination/ interview:
a. High School Certificate in original.
b. Mark sheets of qualifying examination in
original.
c. Character Certificate issued b} the Head
of the Institution last attended/ from employ-
er.
d. Certificate of sponsorship in the pre-
scribed format (if applicable).
e. No. Objection certificate from parent em-
ployer (if applicable).
(ii) The candidates are required to bring fol-
lowing documents at the time of admission:
a. Passport size Photographs ( 4 Nos.).
b. Two set of Self attested copies of al I the
documents I isted above.
c. Admission letter if an) issued b) the Insti-
tute verified document/ Admit Card used for
Admission Test.
Application Procedure:
Note: Those who have applied against ear-
lier Admission Notice No. 344/Acad./17-18
dated 16th October’ 2017. need not to apply
again. Their candidature will be considered
in this round based on the application sub-
mitted by them previously. However. they
have to participate in the selection process
a fresh.
1. All candidates are advised to apply only
through online on NIT Patna website http://
www.nitp.ac.in. Application fees need to be
paid online through Institute website only.
2. After submission of online application,
applicant should dov. nload the printed ap-
plication and send it along with the required
documents, proof of on line pa):ment to the
address given below on or before 3rd April’
2018 by speed/registered post. Application
by hand will not be entertained.
3. Application fee is of Rs. 1500/- for Gen-
eral/ OBC/ Sponsored category and Rs. 750/-
for SC/ ST/ PwD.
4. Applicants from SC/ ST/ PwD category
must enclose Certificate issued by competent
authority to claim relaxation in application
Fee.
Postal Address for applications submis-
sion:
Assistant Registrar (Academic)
National Institute of Technology Patna
Ashok Rajpath, PATNA-800005 (India)
Phone: Office: (0612) 237-1929. 237-0843,
Ext. 247,263, 108; Fax: (0612) 2670631
Institute Web Site: www.nitp.ac.in Email
ID: admission@nitp.ac.in
South Asian University
PhD Biotechnology
Admissions – 2018-19
MSc or MTech degree in any branch of
the Biological Sciences or an MD/MS/MSc
from an institution recognized by the gov-
ernment of any of the SAARC countries,
with the minimum marks required are
eligible to apply for the PhD Programme
in Biotechnology offered at SAU. Check
more details below.
South Asian University (SAU) is an inter-
national university established by the gov-
ernments of the eight member nations of
Vol. 02 NO 9
the South Asian Association for Regional
Co-operation (SAARC) viz., Afghanistan,
Bangladesh, Bhutan, India, Maldives, Nepal,
Pakistan and Sri Lanka. The University, es-
tablished with the aim of evolving a South
Asian consciousness, offers Master’s and
PhD level programmes in Economics, Com-
puter Science, Biotechnology, Applied Math-
ematics, Sociology, International Relations
and Legal Studies.
SAU attracts students from all member na-
tions and its degrees are recognized by all the
eight SAARC countries.
The University currently functions from
its Akbar Bhawan campus in Chanakyapu-
ri, New Delhi. It will eventually move to its
100-acre campus in Maidan Garhi, South
Delhi, which is expected to be ready by the
year 2019.
Admission to PhD programmes:
The following is a list of PhD programmes
offered at SAU. The figures in brackets show
the number of seats available in each pro-
gramme.
Details about the faculty, admission pro-
cedure and the format of Entrance Tests can
be accessed by clicking on appropriate links
below:
Faculty of Life Sciences & Biotechnology
(http://www.sau.int/academics/faculties/
faculty-of-life-sciences-biotechnology.html)
Eligibility Criteria, Admission Procedure
& Details of Entrance Test
(http://www.sau.int/admissions/admis-
sion-notice-2018/52-admissions/2018-ses-
sion/618-phd-biotechnology-entrance-2018.
html)
• Applicants who have not completed
their Master’s level course and are yet
to appear for their last year/semester
exam may also take the Entrance Test.
However, their admission will be sub-
ject to their fulfilling the minimum eli-
gibility criteria of aggregate percentage
of marks at the Master’s level besides
clearing the Entrance Test. Please note
that such candidates will not have any
claim to admission if their results are
not declared and their mark sheets are
not available latest by 26 July 2018
which is the last date for admission.
• The admission procedure for the PhD
programme consists of an Entrance
Test followed by an interview. Stu-
dents are required to score at least 50%
marks in both, the Entrance Test and
the interview separately, to be eligible
for admission.
• Travel Subsidy for Candidates Invited
for Interview: Candidates invited for
the interview will be given a travel sub-
sidy (upper limit INR 5,000) towards
actual travel cost by the shortest route
as per instructions which will be com-
municated to those called for interview.
If candidates from outside India are
unable to travel to New Delhi for the
interview, they can seek permission for
an interview through Skype.
• The pre-PhD course work is compul-
sory for all students and is spread over
the first two semesters and carries 16
credits as follows: course work (14
credits) plus seminar and term paper
(2 credits). Distribution of credits be-
tween the first two semesters is decided
by individual Departments / Faculties.
Next Page>>>>
Vol. 02 NO 9
Some Faculties and Departments may
have a slightly higher credit require-
ment depending on their specific needs.
Candidates are advised to carefully
read Faculty and Department-specific
requirements online.
• At the end of the first year, students
with a Cumulative Grade Point Av-
erage (CGPA) less than 5.0 will be
deemed to have failed and shall leave
the university. There is no provision for
a repeat test for improvement of grades
in any pre-PhD course.
• Students with a CGPA of 6.5 and above
will be considered for direct admission
to the PhD programme as per SAU
regulations. Candidates with a CGPA
above 5.0 but less than 6.5 can opt for
the MPhil programme and complete
their thesis work within a year (8 Cred-
its). If a student has obtained a CGPA of
6.5 or above in his/her course work, but
wishes to pursue the MPhil programme
rather than the PhD programme, s/he
will be permitted to do so. Students
with a CGPA of 6.5 or more in MPhil
are also allowed to register for the PhD
programme. Students with a CGPA less
than 6.5 will leave the university with
1. RECRUITMENT @ KENDRIYA
VIDYALAYA, CHANDIGARH – BIO-
TECH VACANCY
Job Title : PGT – Biology & Biotechnol-
ogy
Eligibility :
• PGT: English, Hindi, Maths, Physics,
Chemistry, Biology, Geography, Histo-
ry, Economics, Commerce & Political
Science – (Master Degree in concerned
subject with 50% marks & B.Ed)
• PGT Bio-Technology: M.Sc/M.Tech
in Biotechnology/M.Sc in Genetics/mi-
crobiology/Life Sciences/Bio Chemis-
try with 50% marks
(https://www.biotecnika.org/2018/02/
recruitment-kendriya-vidyalaya-chandi-
garh-biotech-vacancy/)
an MPhil degree.
• Minimum residency requirement for
PhD is three years after admission.
Students pursuing a PhD degree at SAU
are full-time students and are not permitted
to take up full or part-time work during the
residency period.
Deadline for receiving Application Forms:
20 March 2018
Country-Wise Quota of Seats:
PhD Programmes
The available seats in each programme will
be divided as follows:
• Fifty per cent seats for Indian students
and the remaining 50% seats for all
other seven SAARC countries put to-
gether.
• Two merit lists will be prepared, one
for Indian applicants and the other will
be a combined merit list for the remain-
ing SAARC countries. In view of the
small number of seats available in each
programme, seat reservation for indi-
JOBS
2. KENDRIYA VIDYALAYA RECRUIT-
MENT – 2018 @ HYDERABAD | GOVT
BIOLOGY JOB
Job Title : PGT – Biology
Qualification :
Master Degree from a recognized Universi-
ty with atleast 50%marks in aggregate in the
following subjects:PGT (Biology) – Botany/
Zoology/ Life Sciences/Bio Sciences/ Genet-
ics/ Micro Biology/ Bio Technology/ Molec-
ular Bio/Plant Physiology provided they have
studied Botany and Zoology at Graduation
level.
(https://www.biotecnika.org/2018/02/
kendriya-vidyalaya-recruitment-2018-hy-
derabad-govt-biology-job/)
vidual countries is not possible
Scholarships & Freeships:
(http://www.sau.int/admission/2018/schol-
arships2018.pdf)
Application Fee, Date and Venues for the
Entrance Test:
An Entrance Test will be conducted simul-
taneously throughout the SAARC region on
15 April 2018. The fee for appearing in the
Entrance Test is US $10 or INR 650/-. Appli-
cations for admission will be accepted only
online and payment must be made by credit/
debit cards or net banking. Those who cannot
pay the application fee online still need to fill
and submit the online application form. They
can then courier a bank draft for US$ 10 or
INR 650/- drawn in favour of “South Asian
University” payable at New Delhi to the Dep-
uty Registrar Admissions, South Asian Uni-
versity, Akbar Bhawan, Chanakyapuri, New
Delhi 110021, India. The bank draft must
have the name of the candidate, application
number and the programme applied for at the
back of the bank draft. However, registration
will be done only on receipt of the bank draft.
The following is a list of the main cities
where the Entrance Test will be conducted:
KENDRIYA VIDYALAYA RECRUITMENT –
2018 | CHECK APPLICATION DETAILS
3. GOVT JOB @ KENDRIYA VIDYA-
LAYA, MADHYA PRADESH CHHATAR-
PUR | PGT BIOLOGY VACANCIES
Job Title : PGT – Biology
Qualification :
Master Degree from a recognized Universi-
ty with atleast 50%marks in aggregate in the
following subjects:PGT (Biology) – Botany/
Zoology/ Life Sciences/Bio Sciences/ Genet-
ics/ Micro Biology/ Bio Technology/ Molec-
ular Bio/Plant Physiology provided they have
studied Botany and Zoology at Graduation
level.
(https://www.biotecnika.
org/2018/02/govt-job-kendriya-vidya-
laya-madhya-pradesh-pgt-biology-vacan-
cies/)
February 27th, 2018.
• Kabul (Afghanistan)
• Chittagong and Dhaka (Bangladesh)
• Thimphu (Bhutan)
• Male (Maldives)
• Kathmandu (Nepal)
• Karachi and Lahore (Pakistan)
• Colombo (Sri Lanka)
• India (Bangalore, Chandigarh, Chen-
nai, Guwahati, Hyderabad, Jaipur, Kol-
kata, Lucknow, Mumbai, New Delhi,
Patna and Thiruvananthapuram).
Please indicate the centre of your choice
while filling the application form.
The Entrance Tests will be held in two shifts
on the same day at all the centres as shown
below:
Morning Session : PhD in Biotechnology
A student can register for 2 or more courses
but will be allowed to take the Entrance Test
for 2 subjects at most, one in the morning ses-
sion and one in the afternoon.
Application Deadline – 20th March 2018
4.GOVT TEACHING JOB @ KENDRI-
YA VIDYALAYA, AIR FORCE STATION,
BARNALA
Job Title : PGT – Biology
Qualification :
Master Degree from a recognized Universi-
ty with atleast 50%marks in aggregate in the
following subjects:PGT (Biology) – Botany/
Zoology/ Life Sciences/Bio Sciences/ Genet-
ics/ Micro Biology/ Bio Technology/ Molec-
ular Bio/Plant Physiology provided they have
studied Botany and Zoology at Graduation
level.
(https://www.biotecnika.org/2018/02/
govt-teaching-job-kendriya-vidya-
laya-air-force-station-barnala/)
11
February 27th, 2018.
Job seekers looking for research oppor-
tunities in government institute like Direc-
torate of Environment Dept., Haryana and
you either have a Master’s or PhD Degree
in Botany/Zoology/ Biochemistry, then
check out all of the details posted below.
Area of Work : Climate Change Cell of
Environment Department Haryana
Saha Institute of Nuclear Physics, Kol-
kata hiring for Research Associate. PhD
cell biology, PhD Molecular biology candi-
dates send applications via email to SINP,
Kolkata, as Per the details posted below.
Name of the Position : Research Associ-
ate position
No.of.Positions : 01
PhD Jobs at CSIR-IHBT. Botany, Mi-
crobiology, Life Sciences candidates are
requested to attend the Walk-in-Inter-
view that is scheduled to be held on the
date(s) as mentioned below at CSIR-IHBT,
Palampur:
Job Titles : Project Assistant Level-II
No.of.Posts : 01
Project Title :
“Development of microbial formulations
to serve as stress buster and bio-fertilizer for
improving crop productivity in stressed ag-
12
Position I
Name of the Position : Senior Scientist
No.of.Posts : 01
Pay Scale : 15000· 39100+ 6600 GP
Qualifications :
Ph. D in Environmental Sciences/Bio-
Sciences/Chemistry/Botany/Zoology with 5
Area of Research :
Therapeutic Prevention of Viral Infection.
Tenure :
Initially for 1 (one) year and is renewable
based on the performance.
Age limit :
Maximum 35 years as on 13.03.2018
riculture” (OLP-0042) [Upto March, 2019).
Stipend (Per month) [Consolidated] :
Rs. 36,000/- p.m.
Maximum Age
(As on date of Interview) :
35 years as on 26.02.2018
Essential Qualifications :
PhD in Botany/ Microbiology/ Life Scienc-
es
GOVT RESEARCH SCIENTIST
VACANCIES @ DIRECTORATE OF
ENVIRONMENT DEPT., HARYANA
years experience in the field of Environment
Management or in the scale of Rs. 15600-
39100+6400GP
Position II
Name of the Position : Scientific Officer
No.of.Posts : 01
Pay Scale : 9300· 34800+ 4600 GP
PHD RESEARCH JOB OPENING @ SAHA
INSTITUTE OF NUCLEAR PHYSICS,
KOLKATA
Essential Qualifications :
Candidates with a Ph.D. degree in Molecu-
lar Biology & Cell Biology who has submit-
ted his/her thesis for Ph.D. candidates
Fellowship :
Rs. 28,000/- per month (consolidated).
PHD BOTANY/MICROBIO/LIFE SCIENCES
JOB VACANCY @ CSIR-IHBT
Application Instructions:
Eligible candidates may appear for “Walk-
in-lnterview(s)” on the date, time and place
mentioned above along with an application
on prescribed format which is available on
the CSIR-IHBT, website “www.ihbt.res.in”
along with attested photocopies of testimo-
nials of their age, educational qualifications,
experience, reserved category, etc. at the time
of interview. The positions are purely tem-
porary and co-terminus with the duration of
the project. There will be no right implicit
or explicit for regular position or any post in
CSIR-IHBT, whatsoever. Candidates must
also bring with them original certificates of
Vol. 02 NO 9
Qualifications :
M.Sc. Chemistry/Bio-Chemistry having an
experience of 2 years in the field of Environ-
ment Protection and Conservation.
How to Apply:
The complete application along with gist
of ACR for last 10 years and certificate from
competent Authority should reach this office
through proper channel latest by 12.03.2018.
How to Apply:
Interested candidates are requested to send
application materials (Cover letter, Resume,
two letters of references) directly to dulal.
senapati@saha.ac.in by email by 13th March,
2018 from the publication of the advertise-
ment.
Application Deadline – by 13th March,
2018
testimonials at the time of appearing for the
interview failing which he/she will not be al-
lowed to appear for interview. No TA will be
paid for attending the interview.
• Walk-In Details:
•
• Date of Interview – 26.02.2018
• Time of Interview – 09:30 AM
• Venue of Interview – CSIR-IHBT,
Palampur (H.P)